Navigation Links
Neurologix Completes Additional $7 Million Financing
Date:12/6/2010

ny. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through September 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $58 million and $43 million respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using NLX-P101. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully re
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 PTC Therapeutics, Inc. (NASDAQ: ... at two upcoming investor conferences: - FBR 1 ... in Boston on Wednesday, September 3 ... at The Mandarin Oriental Boston on Thursday, September 4 th ... company update at the Bank of America Merrill Lynch Global ...
    (Date:8/20/2014)... Aug. 20, 2014 Torrance Memorial Medical ... advanced, ventilator technology from Covidien to provide a ... patients. The acute care ventilator is ... to conventional mechanical ventilation, and help clinicians move ... Patients on mechanical ventilation are often sedated to ...
    (Date:8/20/2014)... 2014 Transparency Market ... Acid (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid ... Share, Growth, Trends and Forecast 2014 - 2020". The ... million in 2013 and is anticipated to reach USD ... 3.6% during the forecast period from 2014 to 2020. ...
    Breaking Medicine Technology:PTC Therapeutics to Participate at Upcoming Investor Conferences 2Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4
    ... 6 Dendreon Corporation (Nasdaq:,DNDN) will host a ... 9:00 AM,ET (6:00 AM PT) to review the ... for Prostate AdenoCarcinoma Treatment, also known as D9902B),clinical ... immunotherapy for the treatment of advanced prostate,cancer., ...
    ... Burlington County, New Jersey is the newest study ... Hospital,of Philadelphia today received a contract to manage ... Children,s Hospital will manage local,participation, recruitment and data ... funded by the National Institutes of Health., ...
    Cached Medicine Technology:Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2
    (Date:8/20/2014)... In less than a week the airwaves ... to fight muscle related disease. Helping the huge telethon ... brands through their cause-related marketing heft. With their help ... nearly $60 million. , But for small self-serve business ... cause-related marketing remains decidedly local and, although the money ...
    (Date:8/20/2014)... (PRWEB) August 21, 2014 PAINWeek, ... today announced that Ethan Nadelmann, JD, PhD, will ... Nadelmann is the founder and executive director of ... the United States promoting alternatives to the war ... policy reform, both domestically and internationally, he has ...
    (Date:8/20/2014)... (PRWEB) August 21, 2014 Angeldress.co.uk is ... in the international market. It has earned the trust ... quality products with amazing pricing. Recently, it has unveiled ... dresses online. , This time, the company offers ... outfits. All these fashionable products are offered at promotional ...
    (Date:8/20/2014)... (PRWEB) August 21, 2014 iFitDress.com, the ... latest range of cheap evening gowns . ... most of them are priced under $100. , ... current market. It keeps trying its best to help ... trends; all its members are kind and professional. According ...
    (Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... titled “How to Keep Skin Looking Young at ... of all ages maintain healthy skin . These ... offers age specific suggestions for women ages 25-45 and beyond. ... men and women of any age and includes using sunscreen ...
    Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:PAINWeek Welcomes Ethan Nadelmann, JD, PhD, as Keynote Speaker at 2014 Conference 2Health News:Angeldress.co.uk Now Dazzles With Beautiful Summer Cocktail Party Dresses 2Health News:iFitDress.com Releases a New Range of Cheap Evening Gowns 2Health News:Simon Ourian, Kim Kardashian’s Doctor, On Healthy Skin Suggestions for Every Age 2
    ... to infectious diseases, researchers report , TUESDAY, May 11 ... malaria and blood poisoning account for more than two-thirds ... 5 years of age worldwide, a new report shows. ... birth complications, lack of oxygen during birth and congenital ...
    ... researchers say , TUESDAY, May 11 (HealthDay News) -- Adults ... problems, which can affect their ability to cope with daily ... of community resources, and socializing, a new study finds. , ... ages 19 to 55, and a control group of 47 ...
    ... doses still considered protective, experts say, , TUESDAY, May 11 ... while convenient, doesn,t offer the same protection against falls and ... a new study has found. , What,s more, the research ... of vitamin D, it actually increases the risk of falls ...
    ... neighbourhoods where they perceived traffic made it unpleasant to walk ... who didn,t, according to a new University of Alberta study ... status (SES), and changes in body mass index (BMI) over ... surprise findings in the study, led by Tanya Berry, a ...
    ... ... is currently offering a special discount rate to new patients. For just $49, new patients ... Welcome Exam special. , ... May 11, 2010 -- Dr. Abbas Eftekhari, a respected Culver City dentist who ...
    ... cancer drugs can be used effectively while minimizing ... closely monitored and controlled, a clinical panel has ... hypertension experts together to draft new recommendations for ... cancer. First approved in the mid-2000,s, these drugs ...
    Cached Medicine News:Health News:Almost Half of Deaths in Kids Under 5 Occur in 5 Countries 2Health News:Sickle Cell Disease Tied to Cognitive Difficulties 2Health News:Once-A-Year Vitamin D Megadose Ups Fracture Risk: Study 2Health News:Once-A-Year Vitamin D Megadose Ups Fracture Risk: Study 3Health News:Traffic density and increased BMI linked 2Health News:Culver City Dentist, Dr. Eftekhari, Offers Special Promotion for Welcome Dental Exam 2Health News:Culver City Dentist, Dr. Eftekhari, Offers Special Promotion for Welcome Dental Exam 3Health News:Monitoring and control can limit side effects of promising cancer drugs 2Health News:Monitoring and control can limit side effects of promising cancer drugs 3
    Single Use Loading Units (SULU's) with Titanium Staples for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
    ... The ENDOPATH EZ45 Thoracic Endoscopic Linear ... other minimally invasive surgical procedures for transection, ... be used with staple line buttressing materials ... be reloaded seven times for a total ...
    ... in Open Procedures with Compact Endoscopic Linear ... Cutter is designed to deliver a 45mm ... procedures, while simultaneously dividing the tissue between ... a standard blue cartridge, a thick-tissue green ...
    ENDO CLIP II ML, 10 mm Pistol Grip Single Use Clip Applier with Medium - Large Super Interlock Titanium Clips...
    Medicine Products: